Αρχική World News Experts Urge to Remove Care Inequalities for Adolescents and Young Adults (AYA)...

Experts Urge to Remove Care Inequalities for Adolescents and Young Adults (AYA) with Cancer [ESMO Press Release]

LUGANO, Switzerland; BRUSSELS, Belgium – Adolescents and young adults (AYA) with cancer are often missing out on age-appropriate specialist care owing to a lack of awareness of how their needs differ from those of children and older adults with cancer.

A newly released position paper from the AYA Working Group of ESMO and the European Society for Paediatric Oncology (SIOPE) defines a common vision for improving outcomes for AYAs with cancer in Europe. (1) Its recommendations include cooperation between a diverse range of specialists involved in AYA care, development of services tailored to the needs of AYAs with cancer, and specific measures to get more patients in this age group into clinical trials.

Each year, more than 150,000 people in Europe in the AYA age range of 15-39 years, and over 1.2 million worldwide, are diagnosed with cancer. This is equivalent to nearly 7% of all cancers. (2)

S., a 21-year-old patient with a rhabdomyosarcoma of the trunk, recalls that when he finally received the correct diagnosis, he was told to travel to another city where there was the only specialised centre for his rare cancer. “They told me that even at 21, I would be hospitalised in a paediatric oncology unit, because the only experts for my disease were there,” he says.

ferrari-andrea

“These patients are a unique group who inhabit a middle ground between the paediatric and the adult worlds of oncology, and their management is still a challenge,” underlines Dr Andrea Ferrari, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, lead author of the paper and SIOPE Co-Chair of the joint ESMO/SIOPE AYA Working Group. “They may present with paediatric- or adult-type tumours and there is limited awareness both within the general population and the medical and scientific community that cancer can arise at this age. In addition, there is the serious problem of access to quality care and specially designed clinical trials, and last but not least the specific and complex psychosocial considerations in this age group. Together, these critical determining factors impact on treatment outcomes and optimal care for these patients,” he says.

saloustros-emmanouil

“There is an under-provision and inequity of cancer care offered to this group of patients: ‘speaking the same language’ and fostering professional collaboration are really key to finding common ground and building something which is tailored to the unique needs of these patients,” says Emmanouil Saloustros, Department of Oncology, University Hospital of Larissa, Larissa, Greece, ESMO Co-Chair of the joint ESMO/SIOPE AYA Working Group. 

The ESMO/SIOPE position paper highlights the key challenges of AYA care as a lack of understanding of cancer biology in this group, limited availability of specialised centres with age-appropriate multidisciplinary care and poor access to clinical trials of novel therapies. It also suggests that modest improvements in survival in the AYA age group compared to children and older adults with cancer reflect inequalities in care.

The ESMO/SIOPE AYA joint Working Group is committed to supporting both medical and paediatric oncologists by increasing awareness of AYA patients’ needs, encouraging the development of ad-hoc education and advocating for an increase in research capacities in tumour types. “Educating oncologists on the characteristics of the diseases in this age group is a first step,” says Ferrari. “It is similarly important to raise awareness beyond the medical communities, because the knock-on effects of adolescents and young adults being diagnosed with cancer are far broader and longer term.”

“When I had to move to another city, I had to give up everything – university, my girlfriend, my friends. I packed my luggage with a lot of fear, a little courage and a little determination, and also a lot of hope. And I left for this journey, with uncertain and limping steps,” says S.

The Working Group calls for healthcare professionals from different disciplines, patient advocates and stakeholders to focus collectively on the specific challenges of AYA cancer, taking account of the changing physical and psychosocial needs of patients in this age group.

The position paper also suggests that centralisation of care into dedicated and financially well-supported specialist AYA services and networks is needed to improve care and facilitate access to clinical trials of novel therapies for all eligible patients, with potential for improved outcomes for AYAs with cancer.

S. says: “It is important we can have a way to tell our stories. We feel we have an important responsibility; we are witnesses and together with our doctors, we want to make it known that teenagers and young adults can have cancer too, and they can be cured, but only if they receive the best treatment at the right time.”

ESMO and SIOPE are committed to improving education and care of people with cancer and established the joint Cancer in AYA Working Group in 2015. The goal of the Working Group is to increase awareness among adult and paediatric haemato-oncology communities, enhance knowledge on specific issues in AYA, and ultimately, to improve the care of AYA with cancer across Europe. 

ESMO Press Office: media@esmo.org

SIOP Europe Communications Office: office@siope.eu

References 

  1. Ferrari A, Stark D, Peccatori FA et al. Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). ESMO Open. DOI: 10.1016/j.esmoop.2021.100096 
  2. Barr R, Ries L, Trama A, Gatta G, Steliarova‐Foucher E, Stiller C, Bleyer A. A system for classifying cancers diagnosed in adolescents and young adults. https://doi.org/10.1002/cncr.33041 

Notes to Editors 

  • Although AYA is widely used to denote this patient population, TYA (teenagers and young adults) is also used in some settings. 
  • Among the ‘young’ AYA group, blood cancers (mainly lymphomas and leukaemia) and brain tumours are more common than in other age groups. However, as age increases, solid tumours become more common.  

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

10 Ways You Can Nurture A More Sustainable Garden

Sustainable gardening doesn’t have a firm, technical definition. It’s the concept of using sustainable gardening techniques that not only cause no harm to the...

Cancer Research UK spin-out gets US approval to trial unique T cell therapy

Cancer Research UK’s spin-out, GammaDelta Therapeutics (‘GammaDelta’), has been given approval from the US Food and Drug Administration (FDA) to trial its unique T-cell...

Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy

The ECOG-ACRIN EA1131 study hypothesised that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype triple-negative breast cancer...

Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit [ESMO Virtual Plenary Press Release]

VP6-2021 - IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk,...

Breaking News: Supreme Court Upholds the Affordable Care Act

It’s a great day for cancer survivors. The Supreme Court of the United States (SCOTUS) upheld the Affordable Care Act (ACA), commonly known as...

How Does CAR T-Cell Therapy Work in Treating Cancer?

Craig A. Portell, MD, is an Associate Professor of Medicine at the University of Virginia and a member of the UVA Cancer Center in...